Al's Comment:

 This experimental drug is available via expanded access through xCures (I am a paid consultant for xCures) https://clinicaltrials.gov/ct2/show/NCT04566393

---

Posted on: 03/24/2023

The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models

 

---

Click HERE to return to brain tumor news headlines.